GH Research PLC (GHRS)

NASDAQ: GHRS · IEX Real-Time Price · USD
17.50 -1.71 (-8.90%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap910.36M
Revenue (ttm)n/a
Net Income (ttm)-5.44M
Shares Out52.02M
EPS (ttm)-0.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume313,525
Open18.80
Previous Close19.21
Day's Range16.30 - 19.60
52-Week Range12.38 - 30.43
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About GHRS

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-M...

IndustryBiotechnology
IPO DateJun 25, 2021
CountryIreland
Stock ExchangeNASDAQ
Ticker SymbolGHRS
Full Company Profile

Financial Performance

Financial Statements

News

GH Research Announces Positive Trial Results For Treatment-Resistant Depression

Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ: GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients sufferin...

1 month ago - Benzinga

GH Research Posts Data From Treatment-Resistant Depression Trial

GH Research PLC (NASDAQ: GHRS) has reported the outcome of the Phase 2 part of a Phase 1/2 trial of GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression (TRD). The trial me...

1 month ago - Benzinga

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological diso...

1 month ago - GlobeNewsWire

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological dis...

3 months ago - GlobeNewsWire